ANDA 86330, held by Watson Labs. Hydrochlorothiazide; Reserpine.
As of Nov 16, 2026, ANDA 86330 (Hydrochlorothiazide W/ Reserpine), held by Watson Labs, was first approved by FDA on Jun 12, 1978, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 12, 1978 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrochlorothiazide W/ Reserpine25MG;0.125MG ยท tablet;oral | Hydrochlorothiazide; Reserpine | Discontinued |
| Apr 27, 1989 | Supplement 14Labeling | Approved | None posted |
| Jun 12, 1978 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters